Top Markets
#1 MowCat MowCat +367.01%
#2 龙虾 (Lobster) 龙虾 (Lobster) +68.62%
#3 SODAX SODAX +47.33%
#4 Cortex Cortex +33.11%
#5 DexNet DexNet +23.19%
#6 OpenEden OpenEden +20.03%
#7 MANTRA MANTRA +18.18%
#8 Akedo Akedo +17.22%
#9 Magma Finance Magma Finance +16.03%
#10 wojak wojak +15.31%
Coin of the day
MowCat MowCat
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Biotest AG Biotest AG

Biotest AG

BIO
Classifica tra le azioni #7311
Biotest AG is a German biopharmaceutical company focused on the global... Biotest AG is a German biopharmaceutical company focused on the global development, manufacturing, and commercialization of biological medications. The firm organizes its activities into the Therapy, Plasma & Services, and Other segments. Its product portfolio addresses critical needs in hematology, clinical immunology, and intensive care medicine. Among its offerings are treatments for hemophilia A (such as Haemoctin and Vihuma) and hemophilia B (like Haemonine), covering both acute care and prevention. Biotest also provides therapies for various viral infections, including cytomegalovirus (Cytotect CP), hepatitis B (Fovepta, Hepatect, Zutectra), and varicella zoster (Varitect). Additionally, its products, such as Intratect and IgG Next Generation, are utilized for primary and secondary immune deficiencies, autoimmune disorders, and certain neurological conditions. The company further supplies solutions to manage circulating blood volume (Albiomin, Biseko), address clotting factor deficiencies (Cofact, Fibrinogen), and combat serious infections like community-acquired pneumonia and COVID-19 (Trimodulin), as well as general bacterial infections (Pentaglobin). Established in 1946 as Biotest Serum-Institut GmbH, the company adopted its current name, Biotest Aktiengesellschaft, in 1986. Headquartered in Dreieich, Germany, Biotest Aktiengesellschaft has been operating as a subsidiary of Grifols, S.A. since January 21, 2022.
Prezzo delle azioni
$47.45
Ultima sincronizzazione: 2026-05-13
Capitalizzazione di mercato
$1.63B
Variazione (1 giorno)
2.04%
Variazione (1 anno)
3.15%
Paese
DE
Scambia Biotest AG (BIO)

Categoria

Healthcare
Ricavi di Biotest AG (BIO)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Biotest AG, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Biotest AG da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH